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Abstract 
 Acute Graft-vs.-Host Disease (GVHD) is a serious complication after allografting. 
We carried out an exploratory study to investigate a potential correlation of surface 
antigens on Extracellular Vesicles (EVs) and acute GVHD. EVs were extracted from serum 
samples from 41 multiple myeloma patients who underwent allografting. EVs were 
characterized by flow-cytometry using a panel of 13 antibodies against specific membrane 
proteins which were reported to be predictive of acute GVHD. We observed a correlation 
between 3 potential biomarkers expressed on EVs surface and acute GVHD onset by both 
logistic regression analysis and Cox proportional hazard model. In our study, CD146 
(MCAM-1) was correlated with an increased risk - by almost 60% - of developing GVHD, 
whereas CD31 and CD140- (PECAM-1 and PDGFR-) with a decreased risk - by almost 
40% and 60%, respectively -. These biomarkers also showed a significant change in signal 
level from baseline to the onset of acute GVHD. Our novel study encourages future 
investigations into the potential correlation between EVs and acute GVHD. Larger 
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Introduction 
 Acute and chronic Graft-vs.-Host Disease (GVHD) remain major causes of 
transplant-related toxicity and mortality after allografting1–3. These two syndromes differ in 
clinical characteristics and time of onset. Distinct T cell subsets and cytokines are involved 
in their pathogenesis. Acute GVHD has been associated with increased early mortality. 
The discovery of reliable, non-invasive, prognostic biomarkers of acute GVHD may be a 
major advance to improve clinical outcomes. Several potential biomarkers such as single 
nucleotide polymorphism (SNPs) 4,5, miRNAs6–9, and cytokines, chemokines and their 
receptors10,11, have so far been investigated. Overall, biomarkers may be classified in 
systemic ones, which change their level in response to systemic injury, and organ-specific 
ones which are associated with targeted tissues. Among others, the former include miRNA 
such as miR-423, miR-199a-3p, miR-93, and miR-377; ST2 (suppression of tumorigenicity 
2); and several biomarkers of immune-activation12; while the latter include REG3a, CK-18, 
S100, and TIM-3 for gastro-intestinal GVHD, HGF for liver-GVHD, and elafin for skin-
GVHD12. Several investigational studies showed correlations between single or 
combinations of biomarkers and acute GVHD outcomes. However, no current validated 
test has reliably become available to predict the onset of acute GVHD and/or its response 
to treatment. Extracellular Vesicles (EVs) have recently emerged as a promising new 
category of biological biomarkers in different scenarios. Secreted by many cell types, EVs 
are membrane-enclosed structures which include exosomes, shedding vesicles or 
microvesicles and apoptotic bodies. EVs play an important role in the intercellular crosstalk 
and in direct cell-to-cell interactions, in the interplay between cells and the extracellular 
matrix  - juxtacrine signaling -, in the secretion of soluble factors such as cytokines, 
chemokines, growth factors, and hormones13–15. EVs carry proteins, bioactive molecules, 
DNA and miRNA, and EVs composition may greatly differ depending on patient status and 
cell of origin16.  High concentrations of EVs can be found in blood and urine. Notably, EVs 
can non-invasively be extracted from these body fluids. Cells release EVs under a variety 
of physiological and pathological conditions. Over the past few years, many studies have 
shown that EVs contain nucleic acids and proteins implicated in cancer and in many 
conditions such as neurodegenerative, metabolic, and infectious diseases16–20. 
 In the light of these findings, we carried out an exploratory study to characterize 
EVs surface antigens by flow cytometry and to investigate the potential correlation of 
specific membrane proteins and acute GvHD in a series of multiple myeloma patients who 
underwent allografting21–26. 
©    2017 Macmillan Publishers Limited. All rights reserved.
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Materials and methods 
Patients, transplant characteristics, and graft-vs.-host disease 
 Forty-one multiple myeloma patients who underwent an allograft at our Center were 
included. Patient and transplant characteristics are reported in Table 1. Overall clinical 
outcomes were reported in previous reports27–32. All patients received G-CSF mobilized 
peripheral blood (PB) stem cells as stem cell source and 37/41 (90%) were prepared for 
transplant with a non-myeloablative/reduced intensity conditioning. Non-
myeloablative/reduced intensity regimens consisted of low dose 200 cGy total body 
irradiation (TBI) with/without fludarabine (no.=33/41, 80%) or with fludarabine/melphalan 
with/without low dose TBI (no.=4/41, 10%). During neutropenia, patients received 
prophylactic cephalosporins. Long-term prophylaxis against Herpes Virus and 
Pneumocystis jirovecii was performed in all patients. Pre-emptive antiviral therapy was 
initiated for positive Cytomegalovirus (CMV) antigenemia and/or for CMV DNA viral load 
>10.000 copies/ml in peripheral blood. Irradiated red blood cell units and buffy-coat 
derived platelet units were transfused for hemoglobin levels of < 8 mg/dl and platelet 
counts < 20.000 / ul respectively or as clinically indicated. Acute GVHD was diagnosed 
according to Glucksberg score and clinical diagnosis of chronic GVHD was scored 
following the NIH indications 33,34. The study was conducted after obtaining informed 
consent and according to the Declaration of Helsinki.  
 
Serum samples collection  
 Serum samples were obtained from peripheral blood draws. After collection, 
samples were kept at room temperature (RT) for 30 minutes to allow clotting. Serum was 
than obtained by centrifuging at 1,500 x g for 13 minutes in a refrigerated centrifuge and 
stored at −80 °C until use. For each patient, serum samples were collected before 
transplant, and at the following post-transplant days (median): +28; +58; +92; +119; +147; 
and +179, or at disease relapse. 
 
Extracellular Vesicles extraction  
 Patient serum samples (1 ml each) were thawed on ice. EVs were then precipitated 
by adding 250 l of precipitation solution [composition for 20 ml of solution: 5 g of Poly 
Ethylene Glycol (PEG 35,000; Merck KGaA, Darmstadt, Germany) and 0,25 g of 
Protamine-(P) (Sigma-Aldrich, St. Louis, MO) resuspended in deionized water]35. Samples 
were vortexed for 10 seconds and incubated at 4°C for at least 1h and centrifuged at 1500 
©    2017 Macmillan Publishers Limited. All rights reserved.
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x g at RT for 30 minutes. Supernatant was removed and samples centrifuged at 1500 x g 
at RT for 5 minutes. EVs pellets were re-suspended with 150 l of Roswell Park Memorial 
Institute (RPMI) medium supplemented with antibiotics and antimycotic (Penicillin, 
Streptomycin, Amphotericin b), plus 10 % of DMSO, and stored at -80 °C. EV size was 
characterized by Nano-particle tracking (NTA) analysis. Briefly, EV preparations were 
diluted (1∶100-1000) in sterile saline solution 0.9% and analyzed by using a 
NanosightLM10 instrument (NanoSightLtd., MintonPark, United Kingdom) equipped with 
the nanoparticle tracking analyses 2.0 analytic software36.  
Samples of 3 ml from buffy-coat derived platelet Units were centrifuged at 1500 x g 
at RT for 30 minutes to pellet white blood cells. Supernatant was then centrifuged 3 times 
at 2000 x g at RT for 30 minutes to precipitate platelets. Complete depletion of platelets 
was verified using a Sysmex XS-1000i Dasit cell counter before EVs precipitation.  
 
Extracellular vesicles preparation for flow cytometry analysis  
 EVs were characterized by flow cytometry using Fluorescein Isothiocyanate (FITC) 
or Phycoerythrin (PE) conjugated antibodies. Initial screening was carried out on EVs 
extracted from 9 healthy donors and 2 transplant patients, one with GVHD and one 
without, and included a panel of mouse antibodies against the following 23 markers: 
CD44, CD138, CD146, CD120-, CD8, CD81, CD63, CD25, CD31, CD144, CD14, CD15, 
CD42b, CD9, CD3, CD86, CD45, CD40, CD105, CD30, CD106 (all antibodies from 
Miltenyi Biotech, Bergisch Gladbach, Germany), CD140- (BioLegend, San Diego, CA), 
KRT18 (Abnova,Taiwan). Mouse non-immune isotypic FITC or PE IgGs (Miltenyi Biotech, 
Bergisch Gladbach, Germany) were used as negative controls. Hundred l of FACS flow 
dilution buffer (Becton Dickinson Biosciences, San Jose, CA), filtered using a 0,1 m 
syringe, was added to 1-4 l of EVs, and incubated at RT with antibodies in the dark for 20 
minutes. Reactions were stopped by adding filtered FACS flow dilution buffer (400 l in 
control samples with non-immune isotypic IgGs, and 300 l in study samples with 
antibodies), and immediately acquired using a Guava Instrument (GUAVA easyCyteTM 8, 
Millipore).  
 In the light of expression levels between donors and patients (Supplementary 
Figure 2-5), a second panel of 13 potentially informative GVHD biomarkers was selected 
as study panel: CD44, CD138, CD146, KRT18, CD120-, CD8, CD30, CD106, CD25, 
CD31, CD144, CD86, and CD140-.  
 
©    2017 Macmillan Publishers Limited. All rights reserved.
 6 
FACS measurements and analysis 
 The Millipore GUAVA easyCyte 8 was cleaned using the Guava® Instrument 
Cleaning Fluid (EMD Millipore, Billiberica, MA, USA) and rinsed several times with 
nuclease free water (AMBION) before each measurement. A filtered FACS Flow solution 
(with a 0.1 m syringe filter) was acquired to set gates and to discriminate true EVs events 
from background noise. Signals from EVs samples incubated with non-immune isotypic 
IgG controls were used to differentiate specific from non-specific antibody binding. A total 
of 5,000 events were acquired each time at low speed for each marker to determine a) 
fluorescence mean value; b) percentage of positive EVs for a given marker; c) total EVs 
concentration; d) and concentration of positive EVs for a given marker. Data were then 
analyzed using the GuavaSoft ImCyt 2.5 program.  
 
Statistical analyses 
 Cumulative incidences of acute and chronic GVHD were calculated from the date of 
transplant to the date of onset of GVHD. The estimations were performed considering 
death from any cause as competing event according to the method by Gooley et al.37. 
Patients alive without GVHD were censored at the date last known to be alive. 
Correlations between biomarkers were evaluated by Spearman's rho correlation 
coefficient. Effects of repeated measurements of each marker on incidence of acute were 
analyzed dividing the follow up of each patient in period of 30 days. Patients were 
classified by presence/absence of GVHD (0=absent, 1=present) during each period. In 
case of more than one measurement for a given marker in the same 30-day periods, the 
closest to the date of transplant was considered. Thus, the probability of developing GVHD 
in each period with respect to marker levels, evaluated as both absolute measure and as 
change from pre-transplant values, was calculated by logistic regression model. Effects on 
GVHD incidence were reported as standardized Odds Ratio (OR), reporting the effect for a 
1- standard deviation (SD) increase for a given variable per 1-point increase (relative 
increase of 100%) and corresponding p value for statistical significance. Given that 
analyses were based on repeated measurements on the same patient, ORs were 
estimated controlling the standard errors with the Huber-White Sandwich Estimator38.  
Sensitivity analyses were performed estimating the ORs after an imputation of missing 
values in each 30-day period using the last observation carried out for each individual 
patient. Moreover, for sensitivity analysis, Cox proportional hazard models for acute GVHD 
were estimated using EVs parameters at each time-point as a time varying covariate and 
©    2017 Macmillan Publishers Limited. All rights reserved.
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reporting the Hazard Ratios (HRs) for 1-SD increase. All reported p-values were two-




 Acute GVHD requiring systemic therapy was observed in 23/41 (56%) of patients 
(Table 1). Skin and gastrointestinal tract were the most frequently involved sites. Median 
day of onset (range) was day +40 (+22-+145). Though the analysis of chronic GVHD was 
out of the scope of this study, chronic GVHD was observed in 29/40 (72%) of evaluable 
patients (one patient died within 100 days post-transplant). Cumulative incidences of acute 
GVHD and chronic GVHD at day +100 and +400 respectively were 56.25% and 70.7% 
(Figure 1). Twenty/41 (49%) patients experienced CMV reactivation, but no CMV disease 
within 100 days post-transplant. Median day of CMV reactivation was day +48 (range 27-
81). No other viral infections were documented. Overall, 12/41 (29.2%) patients received 
buffy-coat derived platelet transfusions, only 5/41 (12%) within the 7 days preceding 
sample collection for EVs measurements. 
 
EVs Characterization  
 The initial characterization of EVs surface was carried out with the first panel of 23 
biomarkers previously correlated with GVHD (Supplementary Table 1 and Supplementary 
Figures 2-5). Mean fluorescence measurement and percentage of positive EVs were 
obtained for each marker. Thirteen potentially informative biomarkers were selected for our 
study population in the light of expression levels and their variations over time, and the 
differences between patients and donors (Table 2). Figure 2 illustrates representative 
examples of flow cytometry physical parameter dot plots and of fluorescence distribution of 
EVs after incubation with anti-CD8-FITC, anti-CD31-FITC, anti-CD146-FITC, anti-CD140-
-PE and corresponding negative controls. The difference between the isotype and 
biomarker mean fluorescence distributions represents the biomarker expression level on 
EVs surface. Mean fluorescence, percentage of EVs labelled with anti-CD140--PE and 
total EVs concentration are plotted in Figure 3. Similar plots were obtained for each 
biomarker (Supplementary Figure 1).  
 
Correlation between biomarkers and onset of acute GVHD 
©    2017 Macmillan Publishers Limited. All rights reserved.
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 Table 3 illustrates the association between variation or absolute levels of each 
marker and onset of acute GVHD. Three biomarkers, CD146, CD31 and CD140-, were 
significantly associated with the onset of acute GVHD by both logistic regression analysis 
and by Cox proportional hazard model.  CD146 fluorescence was associated with an 
increased risk of developing acute GVHD (OR 1.57, p=0.040 by logistic regression 
analysis, and HR 1.60, p=0.031 by Cox model). Furthermore, CD31 fluorescence (OR 
0.55, p=0.052 by logistic regression analysis, and HR 0.67, p=0.089 by Cox model), 
CD140- percentage (by LR: OR 0.30, p=0.003 and by CM: HR=0.77, p=0.014) and 
CD140- EVs concentration (OR=0.40, p=0.063 by logistic regression analysis, and 
HR=0.68, p=0.058 by Cox model) were associated with a decreased risk of acute GVHD. 
Two biomarkers, CD8 and CD25, showed ORs ranging from 0.91 to 1.27 indicating a very 
minimal effect even though a statistically significant p value, p<0.001, was observed. Co-
expression of CD31, CD140- and CD146 on EVs surface by 2-color flow cytometry 
showed a rather high association of CD146 with CD31 (65%) and with CD140- 
(Supplementary Figure 6). 
 A monotonic association between biomarkers was observed by Spearman's rank-
order correlation (Table 4, Supplementary Table 2-4). CD146 fluorescence, percentage 
concentration and relative concentration showed a significant correlation with CD44 
(rs=0.60; rs=0.58, rs=0.70, p=0.001), KRT18 (rs=0.54, rs= 0.49, rs= 0.65, p=0.001), CD106 
(rs=0.61, rs=0.58, rs=0.68, p=0.001), CD31 (rs=0.58, rs=0.53, rs=0.68 p=0.001). CD31 
fluorescence, percentage concentration and relative concentration showed a significant 
correlation with CD44 (rs=0.67, rs=0.60, rs=0.82 p=0.001), KRT18 (rs=0.63, rs=0.52, rs=0.76 
p=0.001) and CD106 (rs=0.74, rs=0.68, rs=0.91, p=0.001). No significant correlations were 
observed between CD140- fluorescence and percentage concentration with other 
biomarkers, whereas CD140- absolute concentration was associated with CD44 (rs=0.67, 
p=0.001), CD146 (rs= 0.50, p=0.001), CD106 (rs=0.85, p=0.001) and CD31 (rs=0.82, 
p=0.001). 
 Finally, CD146, CD31 and CD140- also showed a significant change in signal level 
before the onset of acute GVHD: an increase in CD146 and a reduction in CD31 and 
CD140- respectively (Figure 4).  
 The impact of potential confounding factors such as viral infections and/or 
contamination of EVs from platelet transfusions was also investigated. By logistic and Cox 
regression models, CMV reactivation did not appear a confounding factor for the 
correlation between EVs and the onset of aGVHD (Supplementary Table 5). Moreover, 
©    2017 Macmillan Publishers Limited. All rights reserved.
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mean EVs concentration was 10 times lower in samples from 5 buffy-coat derived platelet 
Units as compared with that of all 41 patients: 6.13x109 EVs/ml in platelet buffy-coats and 
6.73x1010 EVs/ml in patient serum samples. Importantly, results of our statistical analyses 
were also confirmed when EVs measurements from samples obtained during the 7 days 
following platelet transfusion were not included (Supplementary table 6). 
  
DISCUSSION 
 An ideal biomarker should specifically and sensitively predict the onset of a 
pathological condition and its course, including response to treatment and clinical 
outcomes. Moreover, it should be obtained through non-invasive procedures and 
evaluated through inexpensive standardized assays.  Acute GVHD incidence varies from 
30% to 60%39 and it remains a major cause of transplant related morbidity and mortality 
despite improvements in HLA-typing, donor selection, and GVHD prophylaxis. Several 
studies on its pathogenesis and potential biomarkers have been published. However, 
predictive biomarkers are still lacking and diagnosis and treatment response rely on 
clinical signs and symptoms, and tissue biopsies.  
 We designed a novel study to explore the potential correlation and roles of EVs and 
acute GVHD. Many factors may involve EVs in acute GVHD including their cells of origin 
and their roles in inflammatory processes. Furthermore, EVs can be easily extracted from 
biological fluids such as blood and urine, making them very attractive for diagnostic 
applications. EVs are also characterised by higher stability under various storage 
conditions as compared with soluble molecules. Moreover, we tried to select a 
homogeneous patient population with the same diagnosis of multiple myeloma, 
transplanted with the same stem cell source (mobilized peripheral blood) and prepared in 
the large majority (90%) with a non-myeloablative/reduced intensity conditioning regimen. 
In fact, biomarkers may potentially be influenced by several factors including age, disease, 
conditioning, GVHD prophylaxis, and all other causes of tissue and/or endothelial 
inflammation. Importantly, we ruled out a potential confounding role of CMV reactivation 
and/or other viral infections in our analysis (Supplementary table 5). Moreover, no patient 
with GVHD was treated with mesenchymal cells which express CD146.               
 A strong potential and statistically significant correlation of three biomarkers 
expressed on the EVs surface of our patients who developed acute GVHD as compared 
with those who did not clearly emerged from this study. While awaiting results from 
©    2017 Macmillan Publishers Limited. All rights reserved.
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prospective studies currently in progress, our preliminary findings are intriguing and highly 
encourage further investigations into the roles of EVs in GVHD.  
 CD146 was associated with an approximately 60% increased risk (Table 3) of acute 
GVHD. This membrane protein, also known as melanoma cell adhesion molecule (MCAM) 
or cell surface glycoprotein MUC18, is used as a marker of endothelial cells, and it is also 
expressed on a subset of CD4+ T cells, and follicular dendritic cells. In 2014, Li et al.44 
investigated the expression profiles on blood cells from 214 recipients of an allograft at the 
onset of acute GVHD. The frequency of Th17-prone CD146+CCR5+ T cells was 
significantly increased in patients with gastrointestinal GVHD and it was higher as early as 
14 days after transplant in patients who would later develop gastro-intestinal GVHD40,41. 
Moreover, an increase of this T cell subset has also been observed in many autoimmune 
diseases and in inflammation driven by autoimmunity42,43. 
 Considering that endothelial damage and neovascularization represent early steps 
in acute GVHD pathogenesis, the use of endothelial markers may be considered a helpful 
support to confirm GVHD diagnosis. Almici et al.44 recently showed that the count of 
CD146+CD106+CD45- circulating endothelial cells (CECs) significantly increased in 
patients who develop acute GVHD. Given that EVs membrane composition relies on the 
cell of origin, CD146(+) EVs may have been shed by a reactive Th17 prone T cell 
population and/or by endothelial cells damaged by cytokine storm and inflammation. 
Interestingly, we also found that CD146 levels were associated with other endothelial 
biomarkers such as CD44 by Spearman's rank-order correlation. CD44, cell-surface 
receptor for hyaluronan (H-CAM) has been correlated with an inhibitory role in 
angiogenesis, endothelial cell vitality and proliferation45.  In our cohort, higher levels of 
CD44+ EVs were observed in patients with acute GVHD. This may be explained with a 
reduction of angiogenesis and impaired endothelial protection. Interestingly, we also 
observed a certain degree of co-expression (>65%) of CD146 and CD31 suggesting that, 
in our patients, EVs may have shared the same endothelial origin (Supplementary figure 
6). These findings should however be confirmed prospectively.      
 CD31 was correlated with an approximately 40% (see Table 3) decreased risk of 
acute GVHD. CD31 is a membrane protein, also known as platelet endothelial cell 
adhesion molecule or PECAM-1, normally found on several cell types including, 
macrophages and Kupffer cells, granulocytes, T cells/ NK cells, megakaryocytes, 
osteoclasts, neutrophils. Platelets also express CD31. We ruled out a potentially significant 
contamination of EVs expressing CD31 from transfused platelet Units. Life-span of 
©    2017 Macmillan Publishers Limited. All rights reserved.
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transfused platelets ranges from 3 up to 7 days 46.Moreover, a clearance time of only a few 
hours for transfused platelet derived EVs has been reported 47. Only 5 (12%) patients 
received buffy-coat derived platelet Units during the 7 days before EVs evaluation. Our 
statistical analyses were invariably confirmed when EVs measurements obtained during 
the 7 days following platelet transfusions were not included (Supplementary table 6). 
Moreover, mean EVs concentration of samples from buffy-coat derived platelet Units is 10 
times lower than that of our patients.  
PECAM-1 is a member of the Ig gene superfamily expressed at high density on the 
endothelial cell borders and, at a lower density, on hematopoietic cells. CD31 has been 
involved in leukocyte trans-endothelial migration both in vitro and in vivo. Cheung et al. 
showed that CD31-induced-signaling pathway plays a key role in preventing inflammation-
induced endothelial cell death48. CD31 immuno-regulatory role is however not limited to 
endothelial cells as both T cells and antigen-presenting cells can express it 49,50. When 
CD31 signaling pathways are triggered, a partial inhibition of T-cell receptor signalling and 
a reduced production of inflammatory cytokines in dendritic cells may follow. CD31 
prevents lymphocyte hyper-reactivity by increasing the activation threshold of T-cell 
receptor signalling, thus enhancing peripheral tolerance. Moreover, excessive immune-
reactivity and susceptibility to cytotoxic killing was associated with a loss of CD31 function. 
CD31 deficient mice displayed accelerated and pronounced tumour rejection, suggesting 
an immune regulatory role of CD3149,51. Notably, some studies showed that CD31 gene 
polymorphisms in donor-derived leukocytes were significantly associated with the 
pathogenesis of acute GVHD52–54. We clearly observed a reduction of CD31 levels in our 
patients who developed acute GVHD. By contrast, CD31 expression may have had a 
somewhat protective role against inflammation and immunity damage in patients without 
GVHD, in keeping with previous studies.  
 Finally, CD140- was also associated with a decreased risk of acute GVHD (Table 
3). This membrane protein is also known as Platelets Derived Growth Factor Receptor 
alpha (PDGFR). While the beta form of the PDGFR is essential for pericytes recruitment, 
blood vessels maturation and angiogenesis55, the alfa variant is important for fibroblast 
migration and wound healing56.  We observed a reduction of CD140- levels in patients 
with acute GVHD. Zhang et al.57 showed that TNF- decreases the expression of PDGFR-
after fibroblast injury. Pro-inflammatory TNF- has an important role in both initiating 
acute GVHD as well as amplifying the disease process once established58. As TNF- 
levels are significantly higher in patient with acute GVHD59, high levels of TNF- could 
©    2017 Macmillan Publishers Limited. All rights reserved.
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decrease PDGFR- reducing fibroblast activation and tissue recovery 60. Overall, this may 
result in increased antigen exposure and alloreactivity as seen during acute GVHD. 
 In summary, our preliminary findings underline a potential role of EVs surface 
proteins as biomarkers of acute GVHD. Larger prospective multi-center studies are 
currently in progress. Moreover, the characterization of EVs and their "biological" content 
may shed new light on the pathogenesis of several inflammatory complications after 
allografting.    
©    2017 Macmillan Publishers Limited. All rights reserved.
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Figure 1.   Cumulative incidence of acute GVHD and chronic GVHD.  
a) Day 100-Cumulative incidence of acute GVHD (56.25%; 95% CI, 40.7–71.8%) b). 24 
month-Cumulative incidence of chronic GVHD (70.7%; 95% CI, 56.3–85.2%). 
 
Figure 2.   Extracellular vesicles (EVs) characterization by light scattering and 
fluorescence.  
Physical parameter dot plots of EVs analyzed after incubation with non-immune isotypic 
FITC and PE-IgG (negative controls) by A) light scattering (forward versus side scattering) 
and by B) side scattering versus fluorescence.  
C) (from top to bottom) Physical parameter dot plots (side versus forward scattering, and 
side scattering versus fluorescence), and EVs fluorescence distribution after incubation 
with (from left to right) anti-CD8-FITC, anti-CD31-FITC, anti-CD146-FITC and anti-CD140-
-PE. R1 and R2: gate regions; dashed lines: threshold to discriminate background from 
positive fluorescence signal. In fluorescence distribution panels, the white area represents 
the fluorescence distribution of EVs incubated with non-immune isotypic FITC or PE-IgG 
(negative controls), while the grey area represents the fluorescence distribution of EVs 
labelled with FITC or PE-antibodies.  
 
Figure 3. EVs Mean Fluorescence, percentage of positive EVs and total EVs 
concentration. 
a) EVs Mean fluorescence level b) Percentage of CD140- positive EVs c) Total EVs 
concentration. Red dots are EVs measurements in patients with acute GVHD, while blue 
dots in patients without acute GVHD. 
 
Figure 4.  Signal level before GVHD onset 
a) CD146 and CD31 Fluorescence levels as relative variation from pre-transplant baseline 
values and onset of acute GVHD onset 
b) CD140- Concentration of positive EVs as absolute levels  
Evs Measurements in patients with acute GVHD (red) and in patients without acute GVHD 
(blue)  
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Table 1. Patient and Transplant Charateristics  
 Number (%) 
Patients 41 
Median age, years (range) 53 (range 34-65) 
Male 27 (66%) 
Multiple Myeloma 41 (100%) 
Myeloablative Conditioning 4 (10%) 
 Bu-Mel 2/4 
 Cy-TBI 12Gy 2/4 
Non Myeloablative Conditioning 32 (78%) 
 TBI 2Gy 23/32 
 Flu-TBI 2Gy 9/32 
Reduced Intensity Conditioning 5 (12%) 
 Flu-Mel 1/5 
 Flu-Mel-TBI 2 Gy 4/5 
Donors  
 Matched Unrelated Donor 7 (17%) 
 HLA-identical Sibling 34 (83%) 
Stem Cell Source  
 PBSC 41 (100%) 
Graft-versus-host-disease prophylaxis  
 CyA+MMF 34 (83%) 
 CyA+MTX 2 (5%) 
 CyA+MTX+ATG 3 (7.3%) 
 Tacrolimus+MMF 2 (5%) 
Acute GVHD grade II-IV 23 (56%) 
 Median day of onset (range) 40 (22-145) 
Acute GVHD Grade III-IV 4 (9%) 
No Acute GVHD 18 (44%) 
Chronic GVHD 29/40 (72%) 
 Median day of onset (range) 187 (77-649) 
Severe Chronic GVHD 10 (34%) 
CMV Reactivation (day 0-100 post transplant) 20/41 (49%) 
Median day of CMV Reactivation (range) 48 (27-81). 
CR= Complete Remission; Bu=Busulfan; Mel=Melphalan; Cy=Cyclophosphamide; TBI= Total Body 
Irradiation; Flu= Fludarabine; PBSC= Peripheral Blood Stem Cells; ATG= Antithymocyte Globulin; CyA= 
Cyclosporine A; MMF= Mycophenolate Mofetil; CMV= Citomegalovirus  
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Table 2.  Panel of potential biomarkers (Guava experiments): antigen, alternative 
definition, ligand and distribution, references on potential correlation with acute 
GVHD. 
 
Antigen  Alternative 
Definition 
Ligand/Receptor Distribution Reference 










CD138 Syndecan-1 Extra Cellular Matrix Plasma cells, pre-B, 





CD146 MUC18, S-endo, 
MCAM, Mel-CAM 











Collagen, type XVII, 






TNF, TNF Nucleated cells aGVHD
21
 
CD8 T8, Leu-2 MHC class I T subset, Thimocytes subset aGVHD
26
 
CD30 Ki-1, Ber-H2 CD153 B
act
, T and NK cells, Reed-
Sternberg cells, anaplastic 










, FDC aGVHD 


















CD144, -Catenin Endothelial, stem cells aGVHD 





























©    2017 Macmillan Publishers Limited. All rights reserved.
 1 
Table 3. Association between marker levels and acute GVHD. Marker analysis by 
30-day time periods (logistic regression analysis) with/without imputation of previous 
values in case of missing data, and by a time varying approach (Cox model-
proportional hazard model). Significant odd and hazard ratios (OR and HR 
respectively) are highlighted in grey. 
 
 
Logistic regression analysis 
Cox Model 
Without Imputation With Imputation 
Change Absolute Change Absolute Change Absolute 




0.64 0.196 0.49 0.179 0.74 0.207 0.65 0.199 1.15 0.717 0.81 0.318 
CD44  Fluo 1.08 0.821 1.74 0.058 0.92 0.777 1.33 0.242 0.92 0.684 0.93 0.739 
HCAM Pos % 0.98 0.948 1.72 0.066 0.86 0.535 1.24 0.367 0.80 0.333 0.83 0.370 
 Pos Conc 0.76 0.518 1.20 0.618 0.71 0.268 1.01 0.983 0.71 0.327 0.74 0.212 
CD138 Fluo 0.76 0.402 0.81 0.462 0.68 0.107 0.88 0.567 0.76 0.426 1.02 0.922 
Syndecan-1 Pos % 0.86 0.650 0.78 0.349 0.77 0.271 0.77 0.179 0.82 0.517 0.85 0.520 
 Pos Conc 0.60 0.150 0.50 0.160 0.67 0.102 0.63 0.167 1.11 0.810 0.79 0.279 
CD146 Fluo 1.35 0.375 1.40 0.183 1.57 0.040 1.44 0.095 1.60 0.031 1.32 0.147 
MCAM Pos % 1.17 0.635 1.37 0.308 1.41 0.142 1.37 0.176 1.27 0.230 1.19 0.404 
 Pos Conc 0.87 0.659 0.96 0.924 1.11 0.648 1.08 0.801 1.21 0.400 1.04 0.842 
KRT18 Fluo 0.65 0.233 0.86 0.596 0.72 0.183 1.08 0.795 0.75 0.163 1.07 0.729 
Cytokeratin-18 Pos % 0.65 0.240 0.88 0.656 0.73 0.210 1.02 0.946 0.67 0.084 1.01 0.948 
 Pos Conc 0.55 0.141 0.66 0.315 0.67 0.135 0.93 0.848 0.79 0.465 1.04 0.841 
CD120- Fluo 1.00 0.992 1.09 0.762 0.78 0.457 1.06 0.811 0.71 0.168 0.92 0.700 
TNFR-1 Pos % 1.06 0.892 1.11 0.756 0.84 0.560 0.92 0.724 0.72 0.211 0.80 0.298 
 Pos Conc 0.63 0.166 0.53 0.173 0.69 0.106 0.66 0.197 0.92 0.844 0.79 0.264 
CD8 Fluo 0.91 0.000 1.09 0.779 0.92 0.000 1.09 0.717 2.48 0.633 1.03 0.904 
 Pos % 1.56 0.070 1.37 0.275 1.21 0.181 1.21 0.460 1.20 0.592 1.09 0.714 
 Pos Conc 1.48 0.063 1.22 0.515 1.18 0.196 1.26 0.312 1.21 0.648 1.17 0.438 
CD30 Fluo 0.76 0.472 1.10 0.729 0.84 0.517 1.08 0.729 0.65 0.202 0.91 0.636 
Ki-1 Pos % 0.80 0.534 1.23 0.452 0.92 0.748 1.07 0.766 0.54 0.104 0.85 0.464 
 Pos Conc 0.64 0.258 0.89 0.696 0.84 0.518 0.89 0.642 0.57 0.177 0.86 0.462 
CD106 Fluo 0.68 0.352 0.84 0.592 0.79 0.395 1.07 0.807 0.68 0.222 0.97 0.915 
VCAM-1 Pos % 0.64 0.124 0.85 0.593 0.78 0.246 0.95 0.833 0.72 0.166 0.85 0.481 
 Pos Conc 0.51 0.059 0.51 0.129 0.65 0.077 0.69 0.242 0.72 0.432 0.79 0.297 
CD25 Fluo 0.85 0.563 1.08 0.819 1.27 0.000 1.25 0.392 1.07 0.440 0.97 0.898 
IL-2Ralpha Pos % 1.08 0.757 1.17 0.588 1.34 0.169 1.14 0.553 0.94 0.764 0.84 0.431 
 Pos Conc 0.98 0.935 1.00 0.991 1.32 0.176 1.07 0.783 0.96 0.882 0.86 0.491 
CD31 Fluo 0.67 0.311 1.05 0.867 0.55 0.052 0.93 0.759 0.67 0.089 0.86 0.498 
PECAM-1 Pos % 0.78 0.415 1.10 0.724 0.69 0.130 0.89 0.594 0.64 0.068 0.78 0.250 
 Pos Conc 0.60 0.158 0.61 0.238 0.65 0.067 0.68 0.205 0.71 0.415 0.77 0.219 
CD144 Fluo 0.72 0.331 0.79 0.488 1.01 0.960 0.94 0.811 1.12 0.602 0.95 0.802 
VE-Cadherin Pos % 0.70 0.283 0.68 0.132 0.94 0.838 0.88 0.577 1.15 0.552 1.01 0.969 
 Pos Conc 0.54 0.105 0.49 0.171 0.77 0.398 0.70 0.300 1.18 0.542 0.88 0.541 
CD86 Fluo 1.46 0.015 1.28 0.309 1.22 0.249 0.87 0.571 0.92 0.713 0.82 0.350 
B7-2 Pos % 1.09 0.724 1.34 0.359 0.92 0.717 0.94 0.832 0.63 0.233 0.96 0.858 
 Pos Conc 0.78 0.456 0.67 0.098 0.68 0.231 0.56 0.022 0.65 0.219 0.77 0.263 
CD140- Fluo 1.25 0.477 0.30 0.003 1.19 0.475 0.54 0.035 1.03 0.926 0.75 0.208 
PDGFRa Pos % 1.40 0.154 0.43 0.012 1.30 0.169 0.58 0.037 1.18 0.826 0.77 0.014 
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Table 4.  Spearman Correlation  








































A. CD44 CD146 KRT18 CD106 CD31 CD140- 
CD44 1      
CD146 0.60* 1     
KRT18 0.61* 0.54* 1    
CD106 0.62* 0.61* 0.64* 1   
CD31 0.67* 0.58* 0.63* 0.74* 1  
CD140- 0.10 -0.001 0.19 0.21 0.14 1 
B. CD44 CD146 KRT18 CD106 CD31 CD140- 
CD44 1      
CD146 0.58* 1     
KRT18 0.52* 0.49* 1    
CD106 0.56* 0.58* 0.52* 1   
CD31 0.60* 0.53* 0.52* 0.68* 1  
CD140- 0.03 -0.07 -0.01 0.17 0.13 1 
C. CD44 CD146 KRT18 CD106 CD31 CD140- 
CD44 1      
CD146 0.70* 1     
KRT18 0.75* 0.65* 1    
CD106 0.80* 0.68* 0.75* 1   
CD31 0.82* 0.68* 0.76* 0.91* 1  
CD140- 0.67* 0.50* 0.61* 0.85* 0.82* 1 
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